Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus upadacitinib + risankizumab for fistulising perianal Crohn's disease
ISRCTN71771495Phase 4Recruiting
- Sponsor
- Imperial College London
- Start
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial in Crohn's disease and anal fistula comparing Upadacitinib monotherapy with Upadacitinib + risankizumab (2 arms). Primary endpoint: Combined clinical and radiological fistula response at Week 24. Started Sep 2026; status: recruiting.
02
Drugs
upadacitinibrisankizumab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on ISRCTN71771495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71771495.